BiotechTube

Nilotinib 300 mg.

ApprovedTerminated
1 views this week 0 watching💤 Quiet
Interest: 35/100
35
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Myeloid Leukemia, Chronic

Conditions

Myeloid Leukemia, Chronic

Trial Timeline

Mar 1, 2013 → Aug 1, 2016

NCT ID
NCT02086487

About Nilotinib 300 mg.

Nilotinib 300 mg. is a approved stage product being developed by Novartis for Myeloid Leukemia, Chronic. The current trial status is terminated. This product is registered under clinical trial identifier NCT02086487. Target conditions include Myeloid Leukemia, Chronic.

What happened to similar drugs?

9 of 20 similar drugs in Myeloid Leukemia, Chronic were approved

Approved (9) Terminated (3) Active (9)
✅Venetoclax + AzacitidineAbbVieApproved
✅Venetoclax + Azacitidine + AzacitidineAbbVieApproved
✅NilotinibNovartisApproved
✅NilotinibNovartisApproved
✅NilotinibNovartisApproved
✅AMN107NovartisApproved
✅AsciminibNovartisApproved

Hype Score Breakdown

Clinical
20
Activity
0
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT02086487ApprovedTerminated

Competing Products

20 competing products in Myeloid Leukemia, Chronic

See all competitors
ProductCompanyStageHype Score
AFM28AffimedPhase 1
11
Venetoclax Combining Chidamide and Azacitidine (VCA) regimen followed by dicitabine combined with liposome mitoxantrone, cytarabine, and G-CSF (D-MAG) regimenCSPC Pharmaceutical Group LimitedPhase 2
42
TERN-701Terns PharmaceuticalsPhase 1/2
36
PRGN-3006 T CellsPrecigenPhase 1
27
Bisantrene Dihydrochloride (high dose) + Bisantrene Dihydrochloride (low dose) + Cytarabine Hydrochloride + Decitabine and cedazuridineRace OncologyPhase 1
15
ZN-d5 ZN-c3 + ZN-c3Zentalis PharmaceuticalsPhase 1/2
14
ZN-d5Zentalis PharmaceuticalsPhase 1
19
VIP943 (QW) + VIP943 (BIW)Vincerx PharmaPhase 1
26
TomivosertibeFFECTOR TherapeuticsPhase 1
23
gemtuzumab ozogamycinChugai PharmaceuticalPhase 3
40
Quizartinib High Dose + Quizartinib Low DoseDaiichi SankyoPhase 2
42
Decitabine + Quizartinib + VenetoclaxDaiichi SankyoPhase 1/2
39
MilademetanDaiichi SankyoPhase 1
29
Quizartinib + Treatment according to Physician's Choice + Standard of Care ChemotherapyDaiichi SankyoPhase 3
32
Quizartinib + Cytarabine + Idarubicin + DaunorubicinDaiichi SankyoPhase 1
29
AC220Daiichi SankyoPhase 2
35
PLX3397 + PLX3397Daiichi SankyoPhase 1/2
32
QuizartinibDaiichi SankyoPhase 2
35
QuizartinibDaiichi SankyoPhase 1
29
Quizartinib + Fludarabine + Cytarabine + Idarubicin + glycosylated G-CSFDaiichi SankyoPhase 1/2
28